CDH19 (Cadherin-19) is a calcium-dependent cell adhesion molecule belonging to the type-II classical cadherin family. It plays a role in cell-cell adhesion, tissue morphogenesis, and nervous system development, particularly in axon guidance and neural circuit formation. CDH19 is selectively expressed in tissues such as the brain, retina, and peripheral nerves, and is implicated in cancer progression, including melanoma and neuroblastoma, due to its role in cell migration and invasion.
CDH19 antibodies are tools for detecting CDH19 expression in research and diagnostics. They help study its biological functions, interactions with proteins like RET receptor tyrosine kinase, and involvement in neurodevelopmental disorders or tumor metastasis. In cancer, CDH19 overexpression correlates with poor prognosis, making it a potential therapeutic target. Antibodies enable immunohistochemical analysis, flow cytometry, and Western blotting to map CDH19 distribution in tissues or assess its role in signaling pathways.
Recent studies explore CDH19-targeted therapies, such as monoclonal antibodies or CAR-T cells, to inhibit tumor growth or disrupt pathogenic signaling in neurological conditions. However, research remains in early stages, requiring further validation of CDH19's mechanistic roles and therapeutic potential across diseases.